{"id":"https://genegraph.clinicalgenome.org/r/f6a0fec8-da26-4af2-9c71-8c3f03a33599v1.1","type":"EvidenceStrengthAssertion","dc:description":"*MFN2* was first reported in relation to autosomal recessive multiple symmetric lipomatosis with partial lipodystrophy (OMIM: 151800) in 2008 (Nicholson et al., PMID 18458227) in a single individual who was homozygous for the p.Arg707Trp variant. We have curated the inheritance pattern forâ€¯*MFN2*-related lipodystrophy as a recessive mode of inheritance as this has been consistently reported since 2008 (Carr et al., PMID 26114802; Sawyer et al., PMID 26085578; Capel et al., PMID: 30158064; Rocha et al., PMID: 28414270).  \n\nOne specific *MFN2* variant, p.Arg707Trp, has been reported in all multiple symmetric lipomatosis with partial lipodystrophy cases to date. The majority of individuals are homozygous for this variant, although the p.Arg707Trp has also been reported in trans with a second *MFN2* variant in several cases, including a multi-exon deletion, an in-frame deletion, and a splice site variant (Carr et al., PMID 26114802; Rocha et al., PMID: 28414270; Braszak-Cymerman et al., PMID: 37162328). Individuals typically present with upper body adipose overgrowth and lipodystrophy in the arms and legs, and most individuals also develop progressive distal weakness and axonal neuropathy. Of note, the severity of lipomatosis is variable (Capel et al., PMID: 30158064). Individuals also develop, hypertriglyceridemia, and hepatic steatosis over time (Sawyer et al., PMID 26085578; Capel et al., PMID: 30158064; Rocha et al., PMID: 28414270) with glucose intolerance progressing over time. Another feature is very low circulating leptin levels and low adiponectin levels (Capel et al., PMID: 30158064; Rocha et al., PMID: 28414270).  Less common features include hearing loss, and precocious puberty (Capel et al., PMID: 30158064, Nicholson et al., PMID 18458227).   \n\nAt least four multiple symmetric lipomatosis with partial lipodystrophy-causing *MFN2* variants have been reported; however, all affected individuals have at least one copy of the p.Arg707Trp allele. Evidence supporting the association of this gene with lipodystrophy includes case-level data, and experimental data. The aggregated score for case-level data is 12 points. Variants in this gene were curated for this summary in 15 probands in 6 publications (PMIDs: 18458227, 26114802, 26085578, 37162328, 28414270, 30158064). More evidence is available to support the gene-disease association in the literature, but as the maximum score for genetic evidence (12 points) has been reached; this has not been curated exhaustively. This gene-disease relationship is supported by functional assays, knock-in mouse models, expression studies, and protein interactions (PMIDs: 26085578, 36722855, 28414270). Total points for experimental evidence are 3.5. Total points for genetic and experimental evidence together are 15.5.  \n\nPer criteria outlined by the ClinGen Lumping and Splitting Working Group, we found differences in inheritance pattern, mutational mechanism, and phenotype for variants causing lipomatosis and lipodystrophy vs. those causing neuromuscular conditions. Therefore, we curated *MFN2* for autosomal recessive multiple symmetric lipomatosis with partial lipodystrophy (OMIM: 151800) and semidominant axonal hereditary motor and sensory neuropathy will be curated separately in split curations.  Of note, heterozygous family members of individuals with *MFN2*-related autosomal recessive multiple symmetric lipomatosis with partial lipodystrophy with mild Charcot Marie Tooth phenotypes have been reported, although unaffected heterozygous carriers have also been described though the extent of detailed phenotyping in those cases is unclear (Capel et al., PMID: 30158064; Sawyer et al., PMID 26085578; Braathen et al., PMID: 20350294). \n\nIn summary, *MFN2* is definitively associated with autosomal recessive multiple symmetric lipomatosis with partial lipodystrophy. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Monogenic Diabetes GCEP on September 10, 2025 (SOP Version 11).  ","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/f6a0fec8-da26-4af2-9c71-8c3f03a33599","GCISnapshot":"https://genegraph.clinicalgenome.org/r/9322bddb-bcdb-466b-acae-058f4a368e01","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/9322bddb-bcdb-466b-acae-058f4a368e01_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10016","date":"2025-09-29T18:01:57.959Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/9322bddb-bcdb-466b-acae-058f4a368e01_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10016","date":"2025-09-10T16:00:00.000Z","role":"Approver"}],"curationReasons":["DiseaseNameUpdate"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9322bddb-bcdb-466b-acae-058f4a368e01_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9322bddb-bcdb-466b-acae-058f4a368e01_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c5677ee3-92bf-4a89-9941-071d8d3b24c7","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6d2c4bc4-0190-445e-9a92-4ad2a5a2eac2","type":"Finding","dc:description":"Rocha et al. demonstrates that MFN2 is expressed in adipose tissue and the mitochondrial network in both normal cells and patient cells. Of note, patient cells exhibit suppressed leptin expression and mitochondrial network fragmentation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28414270","rdfs:label":"Rocha Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9fa33860-a9a3-400d-8158-d616ccfcdf5d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3bf821b1-44cd-41c7-b234-b64b6c330ded","type":"Finding","dc:description":"Co-IP experiments with tagged MFN2 demonstrated that cells with the R707W variant had an impaired ability to form homo-oligomers. Formation of hetero-oligomers with MFN1 was unaffected. MFN2 R707W formed smaller oligomeric complexes compared with wild-type MFN2.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26085578","rdfs:label":"Sawyer 2015 homotypic interactions","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9322bddb-bcdb-466b-acae-058f4a368e01_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/59471519-294d-4bcd-a265-45b3c63beee8","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e91ef2c2-d84a-46df-90e6-fb8d97793dd4","type":"FunctionalAlteration","dc:description":"showed reduced capacity to tubulate mitochondria (see figures 3A and 3B), and the mitochondria were more prone to aggregating in clumps (Fig 3C). ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26085578","rdfs:label":"Sawyer 2015 Mito Morphology"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/fb737098-cf8f-44b4-a323-db41ab445cdd","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/60365a69-6b4d-4571-9a4f-b15cd6b88de5","type":"FunctionalAlteration","dc:description":"Adipose tissue from patients revealed abnormal adipocyte and preadipocyte ultrastructure. Control adipocytes exhibited scattered ovoid mitochondria with narrow cristae (Figure 2A), while adipocytes from P2 and P3 showed thickening of the cytoplasmic rim and proliferation of round, enlarged mitochondria, with fragmented cristae on cross sectional imaging. Affected adipose tissue was transcriptionally distinct from control adipose tissue (Figure 3A), and the most significantly altered pathways are involved in mitochondrial dysfunction and oxidative phosphorylation (Figure 3B). ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28414270","rdfs:label":"Rocha Functional"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/9322bddb-bcdb-466b-acae-058f4a368e01_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d79a98b7-ab72-4303-8077-e5df2c5644f8","type":"EvidenceLine","dc:description":"Decreased points as the mice did not show evidence of lipomas or lipodystrophy, although the relevant cellular processes were affected. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7619eb8-4046-42a9-bf04-c5ab43a9d9df","type":"Finding","dc:description":"While the mice do not perfectly recapitulate the human phenotype (fat mass and distribution, body weight, and systemic glucose and lipid metabolism were not significantly different between KI mice and controls), the KI mice did show mitochondrial fragmentation and decreased serum leptin and adiponectin concentrations. The KI mice also showed activation of the integrated stress response in adipose tissue. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36722855","rdfs:label":" Mfn2R707W/R707W knock-in mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3.5},{"id":"https://genegraph.clinicalgenome.org/r/9322bddb-bcdb-466b-acae-058f4a368e01_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/34621976-6e46-4542-8e7e-51c9246a96b0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/34621976-6e46-4542-8e7e-51c9246a96b0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28414270","rdfs:label":"Rocha Patient P3","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":13,"allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014874.4(MFN2):c.2119C>T (p.Arg707Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252166"}},"detectionMethod":"Quad exome with two affected sibs and unaffected parents. ","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0009125","obo:HP_0001065","obo:HP_0001012"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/d3a860f3-2224-493a-9d97-5b5e33227007_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28414270","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/d3a860f3-2224-493a-9d97-5b5e33227007","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d3a860f3-2224-493a-9d97-5b5e33227007_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/d3a860f3-2224-493a-9d97-5b5e33227007_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overgrown tissue from patients with this variant showed mitochondrial network fragmentation, transcriptional evidence of mitochondrial stress signaling, and other studies of this variant (Sawyer et al. PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/6ce1267b-fa0f-497f-8070-ea78ac15677d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6ce1267b-fa0f-497f-8070-ea78ac15677d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30158064","rdfs:label":"Capel P5","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0000365","obo:HP_0001012","obo:HP_0001397","obo:HP_0009125","obo:HP_0000855"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/1ca1ec8a-1a8c-4413-b547-670693d7a438_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30158064","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/1ca1ec8a-1a8c-4413-b547-670693d7a438","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1ca1ec8a-1a8c-4413-b547-670693d7a438_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/1ca1ec8a-1a8c-4413-b547-670693d7a438_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Sawyer et al. (PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions. Rocha et al. (PMID: 28414270) also functionally demonstrated that this variant results in increased mitochondrial stress signaling, and mitochondrial network fragmentation in affected tissue.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/415be44d-03ed-4bb1-8727-8ad275abe0b1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/415be44d-03ed-4bb1-8727-8ad275abe0b1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18458227","rdfs:label":"Nicholson Individual 3/CMT40","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":5,"allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"detectionMethod":"melting curve analysis followed by MFN2 sequencing","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0009125","obo:HP_0002808","obo:HP_0000365","obo:HP_0040078","obo:HP_0001012","obo:HP_0001288"],"previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/fb3c39d8-0de7-4943-abcb-d755961a41e2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18458227","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/fb3c39d8-0de7-4943-abcb-d755961a41e2","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb3c39d8-0de7-4943-abcb-d755961a41e2_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/fb3c39d8-0de7-4943-abcb-d755961a41e2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Sawyer et al. (PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions. Rocha et al. (PMID: 28414270) also functionally demonstrated that this variant results in increased mitochondrial stress signaling, and mitochondrial network fragmentation in affected tissue. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/25366259-45f3-4319-b663-9343692e181d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/25366259-45f3-4319-b663-9343692e181d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30158064","rdfs:label":"Capel P1","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0000365","obo:HP_0001012","obo:HP_0009125","obo:HP_0001397","obo:HP_0000855"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/19b900e1-cd71-4e66-a571-3bbfe8ac87fa_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30158064","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/19b900e1-cd71-4e66-a571-3bbfe8ac87fa","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/19b900e1-cd71-4e66-a571-3bbfe8ac87fa_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/19b900e1-cd71-4e66-a571-3bbfe8ac87fa_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Sawyer et al. (PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions. Rocha et al. (PMID: 28414270) also functionally demonstrated that this variant results in increased mitochondrial stress signaling, and mitochondrial network fragmentation in affected tissue.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/6b2b697b-0aa9-49c1-8865-4c361d4dd9a7_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b2b697b-0aa9-49c1-8865-4c361d4dd9a7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28414270","rdfs:label":"Rocha Patient P2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":12,"allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"detectionMethod":"Quad exome with two affected sibs and unaffected parents.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0009125","obo:HP_0001012"],"previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/f8edd487-5ddc-47b6-9f73-ecc825cf6ddb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28414270","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/f8edd487-5ddc-47b6-9f73-ecc825cf6ddb","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f8edd487-5ddc-47b6-9f73-ecc825cf6ddb_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f8edd487-5ddc-47b6-9f73-ecc825cf6ddb_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overgrown tissue from patients with this variant showed mitochondrial network fragmentation, transcriptional evidence of mitochondrial stress signaling, and other studies of this variant (Sawyer et al. PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/bc5322fb-872b-4eb2-81b4-e13fd1b12e39_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bc5322fb-872b-4eb2-81b4-e13fd1b12e39","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30158064","rdfs:label":"Capel P2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":10,"allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0000826","obo:HP_0009125","obo:HP_0000855","obo:HP_0001397","obo:HP_0001012","obo:HP_0000821"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/cf41c5bf-7819-42f9-ad60-38a65a0a517a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30158064","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/cf41c5bf-7819-42f9-ad60-38a65a0a517a","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf41c5bf-7819-42f9-ad60-38a65a0a517a_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/cf41c5bf-7819-42f9-ad60-38a65a0a517a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Sawyer et al. (PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions. Rocha et al. (PMID: 28414270) also functionally demonstrated that this variant results in increased mitochondrial stress signaling, and mitochondrial network fragmentation in affected tissue.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/9322bddb-bcdb-466b-acae-058f4a368e01_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6d2d31f1-753f-4315-8b26-486e78c13bf3_proband_segregation","type":"FamilyCosegregation","dc:description":"cannot use LOD score as we don't have at least 3 affected individuals in the pedigree. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26085578","rdfs:label":"Sawyer Family 1","estimatedLodScore":0.85,"family":{"id":"https://genegraph.clinicalgenome.org/r/6d2d31f1-753f-4315-8b26-486e78c13bf3","type":"Family","rdfs:label":"Sawyer Family 1","member":{"id":"https://genegraph.clinicalgenome.org/r/abab02e9-6c56-4c4b-a5b9-b4f37d6567be","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26085578","rdfs:label":"Sawyer Family 1 Case 1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":25,"allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"detectionMethod":"The two affected brothers received exome sequencing, with variants filtered to identify shared rare variants. Their two unaffected siblings did not carry the MFN2 variant in the homozygous or heterozygous state. ","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0009125","obo:HP_0009830","obo:HP_0001012","obo:HP_0000819"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1424513f-f7d4-4ca5-afae-1862798d5453_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26085578","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0000819","obo:HP_0001012","obo:HP_0009830","obo:HP_0009125"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/abab02e9-6c56-4c4b-a5b9-b4f37d6567be"}},{"id":"https://genegraph.clinicalgenome.org/r/85a1f18b-ca8b-4011-92df-54772753ec1a_proband_segregation","type":"FamilyCosegregation","dc:description":"Cannot include LOD score as we don't have enough affected individuals who received sequencing. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28414270","rdfs:label":"Rocha Family 2","estimatedLodScore":0.85,"family":{"id":"https://genegraph.clinicalgenome.org/r/85a1f18b-ca8b-4011-92df-54772753ec1a","type":"Family","rdfs:label":"Rocha Family 2","member":{"id":"https://genegraph.clinicalgenome.org/r/6b2b697b-0aa9-49c1-8865-4c361d4dd9a7"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0003477","obo:HP_0009125","obo:HP_0001012"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/6b2b697b-0aa9-49c1-8865-4c361d4dd9a7"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/cb7849cf-8d30-4eff-88f7-107b8019aeeb_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cb7849cf-8d30-4eff-88f7-107b8019aeeb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26114802","rdfs:label":"Carr Family 4","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},{"id":"https://genegraph.clinicalgenome.org/r/3990fe2c-bc5d-4830-adfb-75a6683720d6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014874.3(MFN2):c.600-?_816+?del","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/216110"}}],"detectionMethod":"The coding exons of MFN2 were Sanger sequenced, and when any variant other than a known common polymorphism was detected, copy number analysis was performed via MLPA. For this particular individual family members were not sequenced. ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001288","obo:HP_0001012","obo:HP_0009125","obo:HP_0000543","obo:HP_0003477"],"secondTestingMethod":"Other","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/60e210a5-c976-42eb-a7db-9e27ad9d14a1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26114802","allele":{"id":"https://genegraph.clinicalgenome.org/r/3990fe2c-bc5d-4830-adfb-75a6683720d6"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/54ad381f-eb0c-44b8-8510-8ace165b23fc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26114802","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/54ad381f-eb0c-44b8-8510-8ace165b23fc","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/54ad381f-eb0c-44b8-8510-8ace165b23fc_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/54ad381f-eb0c-44b8-8510-8ace165b23fc_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Sawyer et al. (PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions. Rocha et al. (PMID: 28414270) also functionally demonstrated that this variant results in increased mitochondrial stress signaling, and mitochondrial network fragmentation in affected tissue.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/60e210a5-c976-42eb-a7db-9e27ad9d14a1","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/60e210a5-c976-42eb-a7db-9e27ad9d14a1_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/60e210a5-c976-42eb-a7db-9e27ad9d14a1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":" Analysis of mRNA isolated from blood of 2 affected individuals with exons 7-8 deletion shows a shortened transcript that may be susceptible to either nonsense mediated decay or if translated it is expected to result in an out of frame MFN2 protein starting at codon 200 followed by premature truncation (PMID: 21715711).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/e59a2fff-301a-428d-8d1d-5cac5949f835_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e59a2fff-301a-428d-8d1d-5cac5949f835","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28414270","rdfs:label":"Rocha Patient P1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":5,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/fb54ac88-2f56-40c9-a905-d7e2c62d26ba","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"MFN2, 3-BP DEL, ARG343DEL","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/2504089"}},{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"}],"detectionMethod":"Trio exome sequencing, but specifically interrogated MFN2 given high suspicion for MFN2 associated MSL. ","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000786","obo:HP_0001012","obo:HP_0009125","obo:HP_0000044","obo:HP_0002750","obo:HP_0003477"],"previousTesting":false,"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/0f478879-f473-4bc4-9cf2-3200b2b20062_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28414270","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/b97ef989-abab-43fa-b111-0b1fa48c4d0b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28414270","allele":{"id":"https://genegraph.clinicalgenome.org/r/fb54ac88-2f56-40c9-a905-d7e2c62d26ba"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/0f478879-f473-4bc4-9cf2-3200b2b20062","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0f478879-f473-4bc4-9cf2-3200b2b20062_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/0f478879-f473-4bc4-9cf2-3200b2b20062_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overgrown tissue from patients with this variant showed mitochondrial network fragmentation, transcriptional evidence of mitochondrial stress signaling, and other studies of this variant (Sawyer et al. PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b97ef989-abab-43fa-b111-0b1fa48c4d0b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b97ef989-abab-43fa-b111-0b1fa48c4d0b_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/b97ef989-abab-43fa-b111-0b1fa48c4d0b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overgrown tissue from patients with this variant showed mitochondrial network fragmentation, transcriptional evidence of mitochondrial stress signaling.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/0e13cf23-19a6-4597-b4b1-f618447f936d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0e13cf23-19a6-4597-b4b1-f618447f936d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28414270","rdfs:label":"Rocha Patient P4","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":13,"allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"detectionMethod":"Sanger sequencing of MFN2 in the proband and her unaffected father. Mother was unavailable. ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0009125","obo:HP_0000858","obo:HP_0003477","obo:HP_0001012","obo:HP_0000124","obo:HP_0000956"],"previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/9c815205-b445-4045-a464-38c563428018_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28414270","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/9c815205-b445-4045-a464-38c563428018","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9c815205-b445-4045-a464-38c563428018_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/9c815205-b445-4045-a464-38c563428018_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overgrown tissue from patients with this variant showed mitochondrial network fragmentation, transcriptional evidence of mitochondrial stress signaling, and other studies of this variant (Sawyer et al. PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/a09d80ca-5cb2-46f8-9f22-87d80a811096_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a09d80ca-5cb2-46f8-9f22-87d80a811096","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26085578","rdfs:label":"Sawyer Family 1 Case 2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":45,"allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"detectionMethod":"Exome sequencing was performed in the two affected brothers looking for shared rare variants. Their unaffected siblings did not carry the MFN2 variant. ","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001012","obo:HP_0001288","obo:HP_0009830","obo:HP_0009125"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2201feec-be6f-41fb-8a80-f1871317501b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26085578","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/2201feec-be6f-41fb-8a80-f1871317501b","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2201feec-be6f-41fb-8a80-f1871317501b_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/2201feec-be6f-41fb-8a80-f1871317501b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"R707W mutant showed reduced capacity to tubulate mitochondria, mitochondria were more prone to aggregation in cells expressing the variant, Mutant cells show reduced ability to form homotypic interactions","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/9e3b364e-08c0-43e4-be65-72367d7990f0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e3b364e-08c0-43e4-be65-72367d7990f0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37162328","rdfs:label":"Braszak-Cymerman Case 1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":33,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},{"id":"https://genegraph.clinicalgenome.org/r/c685e8d0-9aa5-42e5-bf1f-7b1aba297d02","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014874.4(MFN2):c.1496-2A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA338447812"}}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0002155","obo:HP_0009125","obo:HP_0000822","obo:HP_0000819","obo:HP_0002240","obo:HP_0000147","obo:HP_0001397","obo:HP_0003477","obo:HP_0000855"],"previousTesting":true,"previousTestingDescription":"LMNA sequencing (negative)","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/9edebda3-7958-402d-a35c-51f7157accae_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37162328","allele":{"id":"https://genegraph.clinicalgenome.org/r/c685e8d0-9aa5-42e5-bf1f-7b1aba297d02"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/2f62e793-d25e-4af1-9bc2-912a13a2f55f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37162328","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/9edebda3-7958-402d-a35c-51f7157accae","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9edebda3-7958-402d-a35c-51f7157accae_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/2f62e793-d25e-4af1-9bc2-912a13a2f55f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2f62e793-d25e-4af1-9bc2-912a13a2f55f_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/2f62e793-d25e-4af1-9bc2-912a13a2f55f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Sawyer et al. (PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions. Rocha et al. (PMID: 28414270) also functionally demonstrated that this variant results in increased mitochondrial stress signaling, and mitochondrial network fragmentation in affected tissue.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/3eefb400-e86e-4b38-876e-004fd11adcc0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3eefb400-e86e-4b38-876e-004fd11adcc0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30158064","rdfs:label":"Capel P6","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0009125","obo:HP_0001012"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/2804737d-0b56-4217-976e-3057b76b824b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30158064","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/2804737d-0b56-4217-976e-3057b76b824b","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2804737d-0b56-4217-976e-3057b76b824b_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/2804737d-0b56-4217-976e-3057b76b824b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Sawyer et al. (PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions. Rocha et al. (PMID: 28414270) also functionally demonstrated that this variant results in increased mitochondrial stress signaling, and mitochondrial network fragmentation in affected tissue.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/57f31180-d62c-405c-9df1-ab1b5094dffc_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57f31180-d62c-405c-9df1-ab1b5094dffc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30158064","rdfs:label":"Capel P3","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"firstTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/e2f4db59-ac09-4f0e-9a2c-9d966f9be128_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30158064","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/e2f4db59-ac09-4f0e-9a2c-9d966f9be128","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2f4db59-ac09-4f0e-9a2c-9d966f9be128_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/e2f4db59-ac09-4f0e-9a2c-9d966f9be128_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Sawyer et al. (PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions. Rocha et al. (PMID: 28414270) also functionally demonstrated that this variant results in increased mitochondrial stress signaling, and mitochondrial network fragmentation in affected tissue.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/09be7a5d-1b85-4532-bde4-a40f2a81b134_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/09be7a5d-1b85-4532-bde4-a40f2a81b134","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30158064","rdfs:label":"Capel P4","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0000855","obo:HP_0003477","obo:HP_0009125","obo:HP_0001397","obo:HP_0001012"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/ee003b7f-4436-4b88-913f-816bca52a311_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30158064","allele":{"id":"https://genegraph.clinicalgenome.org/r/585c881b-3be9-4fd6-adbe-6900741847c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/ee003b7f-4436-4b88-913f-816bca52a311","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ee003b7f-4436-4b88-913f-816bca52a311_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/ee003b7f-4436-4b88-913f-816bca52a311_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Sawyer et al. (PMID 26085578) demonstrated that the p.R707W variant exhibits reduced capacity to tubulate mitochondria, and mitochondria are more prone to aggregation in cells expressing the variant. Mutant cells also showed reduced ability to form homotypic interactions. Rocha et al. (PMID: 28414270) also functionally demonstrated that this variant results in increased mitochondrial stress signaling, and mitochondrial network fragmentation in affected tissue.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/abab02e9-6c56-4c4b-a5b9-b4f37d6567be_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/abab02e9-6c56-4c4b-a5b9-b4f37d6567be"},{"id":"https://genegraph.clinicalgenome.org/r/1424513f-f7d4-4ca5-afae-1862798d5453","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1424513f-f7d4-4ca5-afae-1862798d5453_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/1424513f-f7d4-4ca5-afae-1862798d5453_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"R707W mutant showed reduced capacity to tubulate mitochondria, mitochondria were more prone to aggregation in cells expressing the variant, Mutant cells show reduced ability to form homotypic interactions","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":11881,"specifiedBy":"GeneValidityCriteria11","strengthScore":15.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Vt8UmSSRc-I","type":"GeneValidityProposition","disease":"obo:MONDO_1060153","gene":"hgnc:16877","modeOfInheritance":"obo:HP_0000007"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_9322bddb-bcdb-466b-acae-058f4a368e01-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}